Program
evobrutinib
Also written as “Evobrutinib”, “M2951” and “MSC2364447C”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid · Autoimmune Diseases, led by Merck KGaA, Darmstadt, Germany.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 200 open or running | phase 3since Jul 23, 2019 | Aug 28, 2015 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Aug 28, 2015.
- May 24, 2016Phase 2 study in Arthritis, RheumatoidNCT02784106 · 65 enrolled · United States, Germany
- Nov 23, 20162 phase 2 studiesNCT02975349, NCT02975336
- Jul 25, 2017Phase 2 study in Arthritis, RheumatoidNCT03233230 · 390 enrolled · United States, Argentina, Bulgaria and more
- Feb 6, 2018Phase 1 study in Renal InsufficiencyNCT03436394 · 31 enrolled · Germany
- Oct 29, 2018Phase 1 study in HealthyNCT03725072 · 6 enrolled · Netherlands
- Apr 29, 2019Phase 1 study in HealthyNCT03934502 · 20 enrolled · Germany
- Jul 23, 20192 phase 3 studies in Multiple Sclerosis, Relapsing-RemittingNCT04032171, NCT04032158
- Mar 17, 2020Phase 1 study in HealthyNCT04314024 · 18 enrolled · Germany
- Apr 6, 20202 phase 3 studies in Relapsing Multiple SclerosisNCT04338061, NCT04338022
- Sep 10, 2020Phase 1 study in Hepatic ImpairmentNCT04546789 · 24 enrolled · Germany
- Jan 4, 2021Phase 1 study in Autoimmune DiseasesNCT04697511 · 16 enrolled · Germany
- Sep 23, 2021Phase 1 study in HealthyNCT05064488 · 40 enrolled · Germany
- Jan 13, 20222 phase 1 studies in HealthyNCT05248945, NCT05245396
- Oct 8, 20252 phase 1 studies in HealthyNCT07214935, NCT07214922
TargetBeta
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07214935Healthy · Germany | 1 | Completed | Aug 25, 2023 | 36 |
| NCT07214922Healthy · Germany | 1 | Completed | Feb 24, 2023 | 28 |
| NCT05245396Healthy · United Kingdom | 1 | Completed | Feb 14, 2023 | 58 |
| NCT05248945Healthy · Germany | 1 | Completed | Jul 18, 2022 | 14 |
| NCT05064488Healthy · Germany | 1 | Completed | Dec 10, 2021 | 40 |
| NCT04697511Autoimmune Diseases · Germany | 1 | Completed | Feb 25, 2021 | 16 |
| NCT04546789Hepatic Impairment · Germany | 1 | Completed | May 16, 2021 | 24 |
| NCT04338061Relapsing Multiple Sclerosis · United States, Belarus, Brazil and more | 3 | Terminated | Oct 2, 2023 | 1,166 |
| NCT04338022Relapsing Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Terminated | Oct 2, 2023 | 1,124 |
| NCT04314024Healthy · Germany | 1 | Completed | Jun 23, 2020 | 18 |
| NCT04032171Multiple Sclerosis, Relapsing-Remitting · United States, Germany | 3 | Terminated | May 20, 2020 | 1 |
| NCT04032158Multiple Sclerosis, Relapsing-Remitting · United States, Germany | 3 | Terminated | Apr 16, 2020 | 3 |
| NCT03934502Healthy · Germany | 1 | Completed | Jun 12, 2019 | 20 |
| NCT03725072Healthy · Netherlands | 1 | Completed | Dec 5, 2018 | 6 |
| NCT03436394Renal Insufficiency · Germany | 1 | Completed | Feb 22, 2019 | 31 |
| NCT03233230Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more | 2 | Completed | Sep 23, 2019 | 390 |
| NCT02975349Multiple Sclerosis, Relapsing-Remitting · Bulgaria, Czechia, Poland and more | 2 | Terminated | Jan 24, 2018 | 267 |
| NCT02975336Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more | 2 | Terminated | Nov 27, 2019 | 469 |
| NCT02784106Arthritis, Rheumatoid · United States, Germany | 2 | Completed | Apr 30, 2017 | 65 |
| NCT02537028Lupus Erythematosus, Systemic · United States, Bulgaria | 1 | Completed | Oct 4, 2016 | 24 |
How it is read
Names in the registry
- “Evobrutinib”, 12 entries
- “M2951”, 7 entries
- “MSC2364447C”, 2 entries
- “Treatment A”, 1 entry
- “Treatment B”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 3 studies
- Multiple Sclerosis, 2 studies
- Lupus Erythematosus, Systemic, 2 studies
- Arthritis, Rheumatoid, 2 studies
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.